Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Silexion Therapeutics Corp

NASDAQ: SLXN · Life Sciences · 9 alerts · CIK 2022416

Share price
$1.76Close, Nov 16
Market cap
$1.14M
Shares outstanding
649.53KLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Silexion Therapeutics Corp filings on SEC EDGAR ↗

8:52 AM ET 8-K
Clinical Trial Data

Silexion Therapeutics Clinical Trial Data

Silexion Therapeutics has successfully dosed the first patient in its Phase 2/3 clinical trial of SIL204 for the treatment of locally advanced pancreatic cancer (LAPC). The trial evaluates SIL204 in combination with standard chemotherapy using a dual-route delivery strategy involving both intratumoral and subcutaneous administration. This milestone marks the transition of the company's lead RNAi program into active clinical execution across sites in Israel and Germany.

Counterparty
Tel Aviv Sourasky Medical Center
10:31 AM ET 8-K
Capital Raise

Silexion Therapeutics Capital Raise of $840K

Silexion Therapeutics entered into an inducement agreement with warrant holders to exercise 3,216,928 existing warrants at a reduced price of $0.2603 per share. In exchange for the cash exercise, the company will issue 6,433,856 new Series F and G warrants to the holders. The transaction is expected to generate gross proceeds of approximately $0.84 million to support the company's operations.

Value
$840K
Counterparty
H.C. Wainwright & Co., LLC
8:47 AM ET 8-K
Clinical Trial Data

Silexion Therapeutics Clinical Trial Data

Silexion Therapeutics announced positive preclinical translational research findings for its lead RNAi candidate, SIL204, demonstrating a mechanism for systemic uptake in KRAS-driven cancers. The study showed that SIL204 utilizes native serum lipids and lipoprotein pathways for cellular entry and gene silencing without the need for artificial nanoparticles, supporting its upcoming Phase 2/3 clinical program.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.